Sangamo Therapeutics

Mark McClung, Chief Business Officer and EVP
Brisbane, CA
(NASDAQ: SGMO)
Sangamo Therapeutics is focused on translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing, and gene regulation. www.sangamo.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions